Diapositiva 19 de 25
Notas:
El caso estudio de las heparinas indica la existencia de varias limitaciones relacionadas con: “estimating the probability for early complications, the assumption that clinical effectiveness was independent of the treatment setting, and nursing time costs of drug administration.”
